Status:
COMPLETED
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborating Sponsors:
Alaska Native Tribal Health Consortium
Southcentral Foundation
Conditions:
Pneumococcal Infections
Eligibility:
All Genders
55-70 years
Phase:
PHASE1
Brief Summary
To test the hypothesis that immune responses to 23-valent pneumococcal polysaccharide vaccine (PPV-23) could be improved in Alaska Native elders by immune priming with 7-valent pneumococcal conjugate ...
Detailed Description
Rates of invasive pneumococcal infection (bacteremia and meningitis caused by Streptococcus pneumoniae) for Alaska Natives are among the highest in the United States and are approximately five-fold hi...
Eligibility Criteria
Inclusion
- Age 55 to 70 years
- Alaska Native
Exclusion
- Immune compromising condition
- Neurological disease
- Immune suppressive medication or immunoglobulin within 6 months
- Previous pneumococcal vaccination
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2003
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT00153543
Start Date
May 1 2002
End Date
June 1 2003
Last Update
October 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alaska Native Medical Center
Anchorage, Alaska, United States, 99508